A New Compound Reverses Memory Deficits in Model of Schizophrenia

Good to see new progress in this area:

New research in mice suggests that memory deficits caused by a 22q11.2 microdeletion, which is the single largest genetic risk factor for schizophrenia, can be treated with antagonists of the glycogen synthase kinase 3 β (Gsk3β) protein (Tamura M et al. Neuron. doi:10.1016/j.neuron.2016.01.025 [published online February 18, 2016]).

Gsk3β is involved in energy metabolism, neuronal cell development, and body pattern formation.



I wish they would update new medicines in research list. Most of the meds on the list are old.

1 Like

Sounds as though it could be very useful. Can only speak as someone who has experienced (mild?) psychosis according to various pdocs.
My long term memory is much better than my short term. I always do badly on those tests where you study a group of words for a short period of time, and then later have to recall as many as possible or are given a word and have to state whether it appeared on the list or not.

1 Like